Thoughts on CMPX 65% drop
Reading the actual results (https://finance.yahoo.com/sectors/healthcare/articles/tovecimig-demonstrates-statistically-significant-benefit-113000084.html) it looks like the drug works, but “failed” in an secondary endpoint because of high crossover with other med, which is not entirely bad Overall this 65% drop feels like an overreaction, did an LLM …